Parisa Kangari - Department of Biology, higher education institute of Rab – Rashid, Tabriz-Iran
Somaiye Ebadollah zade - Department of Biology, higher education institute of Rab – Rashid, Tabriz-Iran
Soltan Ali Mahboob - Department of Biology, higher education institute of Rab – Rashid, Tabriz-Iran
Ali Reza Nourazarian - Department of biochemistry and clinical laboratories, Faculty of medicine, Tabriz Universityof medical sciences, Tabriz, Iran

The aim of the present study was to investigate the level of MDA in the serum of patients affected with breast cancer. Changes in the levels of malondialdehyde (MDA) as an indicator of lipid peroxidation (LPO) is important clinically. So that the assessment of MDA levels is used to diagnosepathological conditions, diseases, and cancer. 38 healthy women as control group whit 38 women newly diagnosed whit breast cancer were studied as target group.Healthy subjects age 39/61±0/926 and breast cancer patients were 40/78±0/847 years old. Blood samples from both groups were collected after overnight fasting and after separating the serum they were kept in -70 until day of examination. In this study serum MDA levels were measured using a chemical method. In this study, a significant increase in the levels of malondialdehyde (MDA) as a marker of lipid peroxidation was seen in breast cancer patients compared whit control subjects(p<0.05). According to the results of this study can be concluded that there is a direct relationship between serum levels of MDA with an increased risk of breast cancer and malondialdehyde can be used as a biomarker for the diagnosis of breast cancer.

breast cancer- malondialdehyde-lipid peroxidation